All In Biotech

Drug Trial Radar · NCT03594435

Ibudilast for the Treatment of Alcohol Use Disorder

A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder

Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Oct 1, 2018

Primary completion

Apr 19, 2023

Study completion Apr 19, 2023

Sponsor

Lead sponsor
University of California, Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA); MediciNova
First posted
Jul 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.

Conditions

  • Alcohol Use Disorder

Interventions

  • IbudilastDrug

    targets neurotrophin signaling and neuroimmune function

  • Placebo oral capsuleDrug

    matched to active drug, ibudilast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Heavy Drinking DaysTime frame: 12 week-treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCLA Addictions Laboratory

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.